New HIV infections have fallen roughly 59% from their 1995 peak, the lowest annual count in decades, while AIDS-related deaths have dropped about 69% since 2004 following the global scale-up of antiretroviral therapy. An estimated 39 million people were living with HIV in 2022, a figure shaped as much by survival gains as by new infections.
You will find region-by-region numbers, the specific drivers behind falling infection rates, and how close the world is to meeting the 95-95-95 targets before 2025.
The Headline Numbers Behind the Global Decline
Annual new HIV infections have fallen from a peak near 3.5 million in the late 1990s to roughly 1.3 million in 2023, a drop of about 59% across nearly three decades. AIDS-related deaths followed a parallel curve, plunging from a 2004 high near 2 million per year to about 630,000 by 2022 after combination antiretroviral therapy became affordable and widely distributed in the hardest-hit regions.
Behind those headline figures sits a quieter but important shift. More people are living with HIV than ever before, around 39 million globally, because treatment keeps people alive longer. A rising total of people living with the virus paired with falling new infections signals a maturing epidemic, not a worsening one.
| Indicator | Latest Global Figure | Change From Peak |
|---|---|---|
| New HIV infections (annual) | ~1.3 million (2023) | Down ~59% since 1995 |
| AIDS-related deaths (annual) | ~630,000 (2022) | Down ~69% since 2004 |
| People living with HIV | ~39 million (2022) | Rising because of survival |
| ART coverage | ~76% of people living with HIV | Up from under 10% in 2003 |
Global ART coverage now reaches about 76% of people living with HIV, a milestone that fundamentally reshapes what controlling the epidemic actually means. When nearly four in five people with the virus have access to medication that suppresses it to undetectable amounts, the population-level dynamics shift from runaway transmission to a slow, manageable burn.
Where Progress Is Strongest and Where It Is Stalling
The global decline is not evenly distributed. Eastern and southern Africa, the region that once carried the heaviest burden, has driven most of the world’s progress, with new infections in countries such as Kenya, Malawi, and Zimbabwe falling by more than half over the past decade. Sub-Saharan Africa still accounts for roughly two-thirds of all people living with HIV, yet its share of new infections is shrinking every year.
Eastern Europe and Central Asia remain the only region where new HIV infections continue to rise, driven largely by injection drug use and the criminalization of harm-reduction services. The Middle East and North Africa and several countries in Latin America are also lagging, where stigma and limited testing access keep people out of the treatment system for years.
Regional snapshot
- Eastern and southern Africa: Sharp declines, sometimes above 60% reduction in new infections over 10 years.
- Western and central Africa: Slower gains; ART coverage still below regional targets.
- Eastern Europe and Central Asia: The only region with rising new infections.
- Asia and the Pacific: Mixed results; large absolute numbers even when percentages fall.
- Middle East and North Africa: Low prevalence but very slow reduction in stigma-driven transmission.
- Latin America: Stalled in several countries where key populations cannot access prevention.
- Caribbean: Steady progress, now approaching elimination thresholds in a few small states.
A national headline number can hide very different realities inside a single country. Relying only on a national average is one of the easiest ways to draw the wrong conclusion about whether HIV is declining globally.
That uneven pattern raises a sharper question: what is actually pushing infection rates down in some places and allowing them to stall in others?
The Drivers Behind Falling Infection Rates
Four interlocking forces explain most of the worldwide decline in new HIV infections, and each one has a measurable signature in the data. None of them works alone, and removing any single one slows the curve.
Treatment that prevents transmission
Widespread access to antiretroviral therapy suppresses viral loads in the blood to undetectable levels, which eliminates the risk of sexually transmitting HIV to others. A person who takes medication as prescribed and stays virally suppressed cannot pass the virus on, a finding confirmed across multiple large studies and now codified in the global prevention message Undetectable = Untransmittable.
Prevention options beyond condoms
The expansion of pre-exposure prophylaxis gives high-risk populations a powerful tool to stay HIV-negative. Daily oral PrEP, and more recently long-acting injectable PrEP, has cut new infections by more than 90% among users who adhere to it, turning prevention into a choice you can make for yourself.
Targeted biomedical and behavioral tools
Targeted testing programs, treatment-as-prevention strategies, and voluntary medical male circumcision together reshape transmission dynamics in the regions where they are deployed at scale. Voluntary medical male circumcision alone has prevented an estimated 300,000 new HIV infections in eastern and southern Africa since 2008.
Community-led outreach and harm reduction
Local peer educators and harm-reduction teams still receive only a sliver of the funding needed to keep their life-saving work going. Where peer workers and drop-in centers operate openly, new infections fall faster than the regional average; where they are shut down, transmission rebounds within months.
Practical tip: Effective HIV programs pair biomedical tools (ART, PrEP, circumcision) with community-based services that reach the people most at risk. Removing the community layer while keeping the medical tools rarely produces sustained declines.
Key Populations and the Limits of the Global Average
Sex workers, men who have sex with men, people who inject drugs, and transgender people account for a disproportionate share of new HIV infections worldwide, and the share is growing even as the overall curve falls. In several regions, new infections are concentrated almost entirely among these groups, even when the national rate drops, because the broader population is already saturated with prevention and treatment.
Punitive laws, criminalization, and stigma push these groups away from testing and treatment services. When possession of condoms or clean syringes can be used as evidence of a crime, people stop carrying them. When clinics require ID or disclose status to authorities, people stop walking in. The epidemic then concentrates in the very communities the public health system is failing to reach.
Where the gap is widest
- Sex workers: 30 times higher odds of acquiring HIV than the general adult population in many low- and middle-income countries.
- Men who have sex with men: Account for the majority of new infections in Latin America, parts of Asia, and several high-income countries.
- People who inject drugs: Drive the rising regional curve in Eastern Europe and Central Asia.
- Transgender people: Bear elevated risk in every region where data is collected.
Reaching these communities is the single biggest lever for closing the remaining gap toward elimination, because their share of new infections determines where the curve eventually settles.
That imbalance in who is being left behind is now reshaping how the targets themselves are measured.
Reading the 95-95-95 Targets in Current Numbers
The 95-95-95 targets are the operational definition of epidemic control: 95% of people living with HIV know their status, 95% of those diagnosed receive sustained antiretroviral therapy, and 95% of those on treatment achieve viral suppression. Hit all three, and transmission effectively stops because the pool of people who can pass the virus on becomes vanishingly small.
Where each target stands
- First 95 (know your status): Met globally as an average, around 86% of people living with HIV knew their status in 2022, with wide variation by country and age group.
- Second 95 (linkage to ART): On track in many African nations, with linkage above 90% in several, while lagging in Eastern Europe, the Middle East, and parts of Asia.
- Third 95 (viral suppression): Marks the threshold at which transmission effectively stops; reached by roughly 71% of all people living with HIV globally.
Several high-burden countries are close to meeting all three targets simultaneously, while others remain years behind the 2025 deadline. Eswatini, Rwanda, and Switzerland have already crossed the 95-95-95 threshold at the national level, demonstrating that the targets are achievable when the political and financial commitment exists.
| 95-95-95 Stage | Global Average | Status |
|---|---|---|
| Diagnosed | ~86% | Met as an average |
| On treatment | ~76% of all people with HIV | Close to target |
| Virally suppressed | ~71% | Closing in |
Funding Gaps, Conflicts, and the Road to 2030
Donor funding for HIV programs has plateaued, and several major donors have announced reductions that threaten prevention gains in countries that depend on external support for testing, treatment, and community outreach. UNAIDS has estimated that sustained under-investment could lead to an additional 2.6 million HIV-related deaths between 2025 and 2029 if current funding trajectories continue.
Conflict zones and humanitarian crises disrupt medicine supply chains and clinic access, risking rebound outbreaks. Sudan, Ukraine, and parts of the Democratic Republic of Congo have all seen stockouts of antiretrovirals in recent years, and each stockout translates into people who stop treatment, lose viral suppression, and become infectious again.
Heads up: Treating HIV as a solved problem leads to budget cuts that reverse progress within a few years. Every interruption of treatment creates both individual health risk and renewed transmission risk for partners.
UNAIDS’ goal of ending AIDS as a public health threat by 2030 remains technically plausible but politically fragile. Maintaining current momentum requires renewed financing, legal reform for key populations, and the integration of HIV care into broader health systems, including tuberculosis, maternal health, and primary care clinics.
None of that, however, happens without the financing and political conditions the next section examines.
Bottom Line on Global HIV Decline Trends
New HIV infections are falling, AIDS deaths have dropped by roughly 69% since 2004, and ART coverage now reaches about three-quarters of everyone living with the virus. The remaining gap is concentrated in regions where stigma, criminalization, and flatlined funding block the same tools that drove the first three decades of progress.
FAQ
Is HIV declining globally?
Yes. New HIV infections have fallen roughly 59% from their 1995 peak, and AIDS-related deaths have dropped about 69% since 2004. The decline is uneven, with Eastern Europe and Central Asia the only region still seeing rising infections.
What are the latest global HIV statistics?
Around 1.3 million new infections and about 630,000 AIDS-related deaths occurred in the most recent reporting year, while roughly 39 million people were living with HIV. ART coverage had reached about 76% of people living with HIV worldwide.
How many new HIV infections occur each year?
Approximately 1.3 million new infections occurred in 2023, the lowest annual figure in decades and down from about 3.5 million at the 1995 peak. Regional variation is wide, with sub-Saharan Africa carrying the largest share of that total.
Which regions have seen the biggest drop in HIV cases?
Eastern and southern Africa have driven most of the global decline, with countries such as Eswatini and Zimbabwe cutting new infections by more than half over the past decade. Eastern Europe and Central Asia remain the only region where new infections continue to rise.
Is the HIV epidemic coming to an end?
Not yet. UNAIDS targets ending AIDS as a public health threat by 2030, and several countries have already hit the 95-95-95 thresholds, but progress depends on sustained funding, legal reform for key populations, and treatment continuity in conflict zones.
What factors are driving the decline in HIV infections?
Antiretroviral therapy that suppresses viral load, expanded access to pre-exposure prophylaxis, voluntary medical male circumcision, targeted testing, and community-led harm reduction together explain most of the global decline. Removing any of these layers tends to reverse gains quickly.
